A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Clinical trial NCT03592264 · TERMINATED

Trial details

NCT number: NCT03592264
Sponsor: OBI Pharma, Inc
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor Pancreatic Adenocarcinoma

Start date: 2018-07-02
Primary completion: 2024-02-13
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.